Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-3,155
Closed -$257K 279
2024
Q3
$257K Buy
3,155
+105
+3% +$8.4K 0.03% 275
2024
Q2
$226K Sell
3,050
-9,607
-76% -$720K 0.03% 274
2024
Q1
$987K Sell
12,657
-256
-2% -$19K 0.12% 146
2023
Q4
$923K Sell
12,913
-155
-1% -$10.8K 0.12% 150
2023
Q3
$907K Sell
13,068
-3,057
-19% -$231K 0.13% 141
2023
Q2
$1.31M Buy
16,125
+2
+0% +$163 0.19% 117
2023
Q1
$1.3M Buy
16,123
+154
+1% +$12.4K 0.2% 118
2022
Q4
$1.19M Buy
15,969
+858
+6% +$61.1K 0.18% 122
2022
Q3
$975K Buy
15,111
+20
+0.1% +$1.39K 0.16% 129
2022
Q2
$1.05M Buy
+15,091
New +$1.12M 0.16% 126
2020
Q3
Sell
-3,864
Closed -$220K 260
2020
Q2
$220K Buy
+3,864
New +$190K 0.04% 231
2017
Q1
Sell
-6,615
Closed -$265K 192
2016
Q4
$265K Hold
6,615
0.06% 167
2016
Q3
$257K Buy
+6,615
New +$250K 0.06% 159

Other funds holding HOLX

Cypress Capital Group's HOLX Position: Q4 2024 in Review

Cypress Capital Group sold out of Hologic (HOLX) in Q4 2024, closing a stake of 3,155 shares — an estimated $257K sold.

Cypress Capital Group first reported a position in HOLX in Q3 2016 and held it in 13 quarters. The position peaked at $1.31M in Q2 2023. 718 funds tracked by Wall St. Rank hold HOLX as of Q4 2024.

  • Cypress Capital Group reported no remaining Hologic position as of Q4 2024 after selling out during the quarter.
  • Cypress Capital Group sold 3,155 Hologic shares in Q4 2024, an estimated $257K.
  • Cypress Capital Group first reported a position in Hologic in Q3 2016 and held it in 13 quarters.
  • Cypress Capital Group's Hologic position peaked at $1.31M in Q2 2023.
  • 718 funds tracked by Wall St. Rank held Hologic as of Q4 2024.

Based on Cypress Capital Group's 13F filing for Q4 2024, filed 6 Feb 2025.